Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026TH OpenOpen Access

Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag

View Full Paper
Ask AI
Bookmark
Share

Authors

QHQuentin A. HillLeeds Teaching Hospitals NHS TrustFZF ZajaUniversity of TriesteMMM Miño MoraHospital Universitario Reina Sofía

Discussion

Loading...

Member takes

Implication

Retrospective chart review shows improved platelet counts in adults with immune thrombocytopenia treated with avatrombopag, suggesting real-world effectiveness.

Key Points

  • The aim is to evaluate the real-world effectiveness of avatrombopag for treating immune thrombocytopenia (ITP) in adults.
  • Multi-center retrospective chart review in Europe
  • Included adults with primary ITP treated with avatrombopag
  • Follow-up duration of at least 12 weeks before and after treatment
  • 96% and 93% of patients achieved platelet counts of ≥30 × 10^9/L and ≥50 × 10^9/L by week 12, respectively.
  • Complete response rates of 72% by week 12 and 87% by week 52 post-index.
  • Thromboembolic rates were 4.9 per 100 patient-years during follow-up.

Cite This Study

Hill et al. (2026) studied this question.

synapsesocial.com/papers/6a65a76fd3aea3239cd783a0https://doi.org/10.1055/a-2886-7426
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‐world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag/hetrombopag2024 · 2 citations
  2. 2Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists2021 · 116 citations
  3. 3Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (<scp>ITP</scp>) for up to 1 year and in those with chronic <scp>ITP</scp> for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies2019 · 67 citations
  4. 4Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China2023 · 18 citations
  5. 5Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia2023 · 14 citations